New £700k Innovate UK grant for FLORA programme

Calla Lily Clinical Care has been awarded a £700k Innovate UK grant through the Growth Catalyst: Investor Partnerships programme, supporting FLORA, a £1M project to adapt our Callavid® intravaginal delivery platform for live biotherapeutic products and probiotics.
FLORA (Focused Lactobacillus Optimised Retention and Adhesion) will optimise the delivery, transfer and retention of beneficial Lactobacillus species. The project will also develop a laboratory model of bacterial colonisation to inform future product development.
Vaginal dysbiosis, most commonly bacterial vaginosis, is linked to increased risk of STIs, miscarriage, preterm birth and poorer IVF outcomes. Treatment remains largely antibiotic-based, and BV recurs in around 58% of women within 12 months, adding to antimicrobial resistance. A timely focus during *World AMR Awareness Week*.
FLORA is the third application of Callavid® to secure independent, competitive funding:
💊 Progesterone for threatened miscarriage, with NIHR
🦠 Targeted antibiotic delivery, with Wellcome Leap
🌱 Live biotherapeutics and probiotics, with Innovate UK
This is our third Innovate UK award. Thank you to Innovate UK for their continued support of women’s health innovation.
Full press release here.



